US-based biotechnology company Nimbus Therapeutics attracted $65m in funding yesterday from its existing shareholders, which include pharmaceutical firms Pfizer, GlaxoSmithKline, Eli Lilly and life sciences software developer Schrödinger.
All but Schrödinger invested through their respective corporate venturing units, Pfizer Venture Investments, SR One and Lilly Ventures. They were joined by Atlas Venture, Lightstone Ventures and private investor Bill Gates.
Nimbus Therapeutics is working on treatments in the areas of immunology, oncology and metabolic disease, using computer-driven drug discovery and development.…
